Navigation Links
Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
Date:4/17/2009

ceive from Servier upfront payments totaling $11 Million on signing the contract and an additional guaranteed $4 Million for research collaboration over a 24 month period, paid in equal increments every 6 months with the initial payment due October 1, 2009. Servier will pay for all development costs outside the United States. In addition Pharmacyclics will receive $24.5 Million based on the achievement of certain milestones up to and including commercialization.

"The collaboration will focus on the clinical development of PCI-24781, as well as to support ongoing research and development of novel, increasingly selective HDAC inhibitors and gives us the opportunity to rapidly bring to market innovative, best-in-class treatments for cancer patients," said Dr. Maky Zanganeh, Vice President of Business Development for Pharmacyclics.

"The combination of Servier's outstanding clinical team with Pharmacyclics' research expertise in novel, small molecule inhibitors of Pan HDAC enzymes, presents a unique opportunity to develop this exciting new class of drugs to its full therapeutic potential," said Dr. Joseph J. Buggy, Vice President of Research for Pharmacyclics.

Pharmacyclics also announced today it will hold a conference call to announce its third quarter fiscal 2009 financial results and achievements. The call is scheduled for April 23, 2009, at 11:00 a.m. EDT (8:00 a.m. PDT). To participate in the conference call, please dial 866-727-3220 for domestic callers and 706-643-1591 for international callers. The conference ID is 95994112. To access the audio broadcast or the subsequent archived recording, log on to http://www.pharmacyclics.com. The archived version of the webcast will be available on the company's website for one month.

ABOUT SERVIER

'/>"/>
SOURCE Pharmacyclics, Inc.

http://www.pharmacyclics.com

SOURCE Pharmacyclics
Copyright©2009 PR Newswire.
All rights reserved


Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
2. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
3. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
4. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
5. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
6. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
7. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
8. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
9. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
10. Premier Research Announces Milestone Investigational New Drug Application
11. PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 According to a ... Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) ... Forecast, 2013-2019" the global endoscopy devices market was valued ... to grow at a CAGR of 6.8% from 2013 ... 36.9 billion in 2019. Browse the full ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... YORK, Sept. 30 Reportlinker.com announces that a new market ... Drug Patent Inventor Report 2010 ... Report profiles the individuals, US states, and countries leading pharmaceutical ... to 2009, this report provides complete lists of: ...
... (Nasdaq: CLSN ), a leading oncology drug ... patients enrolled in its pivotal Phase III ThermoDox ® ... the Data Monitoring Committee (DMC) has unanimously recommended that ... of reaching the 600 patients required to complete the ...
Cached Medicine Technology:Reportlinker Adds Drug Patent Inventor Report 2010 2Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer 2Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer 3Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer 4
(Date:7/11/2014)... -- People with the lowest incomes may have a higher ... a new study suggests. People with PAD have narrowing ... often the legs. The condition causes leg pain and is ... body. People with PAD have a higher risk for heart ... people with PAD who took part in the U.S. National ...
(Date:7/11/2014)... The report, “Specialty Synthetic Fibers & Glass ... 2018,” defines and segments the specialty synthetic fibers ... forecast of the volumes and values of types ... aramids, UHMW Polyethylene, carbon fiber, partially oxidized polyacrylonitrile ... PBO fiber, and liquid crystal polymer fiber and ...
(Date:7/11/2014)... News) -- In people with sex addiction, pornography affects ... seen in drug addicts as they consume drugs, a ... brain activity between patients who have compulsive sexual behavior ... addicts," study author Dr. Valerie Voon, of the University ... release. Voon,s research involved 19 men with sex ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, Inc. ... to cell and gene therapies for cancer – ... organization as Senior Development Officer. , Corday is ... gifts and addressing influential donors. Prior to joining ... NewYork Presbyterian Hospital/Columbia University Medical Center, where he ...
(Date:7/11/2014)... 2014 As reported by the ... 7/11/14), a significant number of severe adverse events such ... and even death from the highly-promoted and costly immune-system ... Times report , a regulatory filing revealed that ... patients was almost 14% of prescriptions, up from 9.1% ...
Breaking Medicine News(10 mins):Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3
... many human beings. A new Mayo Clinic study reveals the ... definition of contact dermatitis is that it is a skin ... direct contact with an allergen. ,The ten allergens ... ,? Nickel (nickel sulfate hexahydrate ,? Gold (gold sodium ...
... data on men's health over the last two decades. The ... a semi annual survey.// Judging by the response, the Harvard ... on how men can maintain a satisfying sex life, as ... most prevalent illness in elderly men followed by chronic illnesses ...
... Mumbai were crippled as the striking doctors were determined to ... All the government hospitals in Mumbai suffered due to absence ... 15 government-managed hospitals in this bustling city of over 15 ... demanding better security while on the job after relatives of ...
... Cyriac Joseph has expressed the need for quality medical ... not leave any stone unturned to weed out black ... this is a matter of grave concern to the ... The educationists, professionals, governments and all the stakeholders in ...
... from Duke university Medical Center have established that ... influenced by a complex interplay between genetic and ... crucial role in determining the psychological and biological ... results of four such studies that examined the ...
... that the much dreaded bird flu virus may be carried across ... the potential of posing a serious health hazard, specifically in the ... bird flu viral strain. ,The exact mechanism of how ... if bird flu virus is found in birds in U.K, it ...
Cached Medicine News:Health News:Health Services Came To A Halt As Mumbai Doctors Strike Continues 2Health News:Genes And Environmental Factors Determine Stress Response 2
Curved shafts with 2.0 mm wide serrated tips and 0.4 mm pin in upper jaw. Serrated cross action handle with dull finish....
Angled insertion forcep used for the Hydroview lens. Manufactured in titanium....
Biconvex jaw design. 40 degree angled shafts. Tip to angle length: 7.5 mm. Locking handle. Manufacturing in titanium....
Titanium. Designed to easily fold the hydroview lens. Will also fold many styles of soft intraocular lenses. Unique cross-action design facilitates folding of the lens....
Medicine Products: